C4 Therapeutics, Inc. (CCCC) Tops Q3 EPS by 3c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.35), $0.03 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $15.36 million versus the consensus estimate of $5.9 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC Capital Starts Centene (CNC) at Sector Perform
• CopperTech Metals files for IPO on NYSE under ticker CUX